Alpha Cognition Granted US Patent for Tablet Form of Neurodegenerative Drug
Alpha Cognition, a biopharmaceutical company focused on novel therapies for neurodegenerative disorders, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application on their lead asset. The patent, titled “Coated Tablets for pH-Dependent Release of Benzgalantamine,” covers tablet forms of benzgalantamine (ZUNVEYL). Once granted, this patent will protect the current formulation of ZUNVEYL in the U.S. through 2044, complementing the company’s existing benzgalantamine patents. 
Alpha Cognition Granted US Patent for Tablet Form of Neurodegenerative Drug